Brands, Medical Use, Clinical Data
Drug Category
- Cardiovascular Agents
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Vasopeptidase inhibitor
- Protease Inhibitors
Dosage Forms
Brands / Synonyms
Omapatrilat [Usan]; Vanlev
Indications
For the treatment of hypertension
Pharmacology
Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.
Mechanism of Action
Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
Absorption
The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.
Toxicity
Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema
Biotrnasformation / Drug Metabolism
Hepatic
Contraindications
Not Available
Drug Interactions
Drug Interactions for Omapatrilat
Drug and food interactions have not been observed with Omapatrilat drug. It is assumed that omapatrilat would have some of the same drug interactions as ACE inhibitors. Some common drug interaction for ACE inhibitors are: Allopurinol,
Aspirin,
Azathioprine,
Lithium,
Potassium supplements,
Potassium sparing diuretics,
and Trimethoprim.
No drug interaction were found when Warfarin was co-administered with omapatrilat.
|
